Literature DB >> 18166775

Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.

N Masera1, C Rescaldani, M Azzolini, C Vimercati, L Tavecchia, G Masera, V De Molfetta, P Arpa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18166775     DOI： 10.3324/haematol.11782

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Ophthalmic Evaluation in Beta-Thalassemia.

Authors:  Rashid H Merchant; Hrishikesh Punde; Neepa Thacker; Deepak Bhatt
Journal:  Indian J Pediatr       Date:  2017-04-03       Impact factor: 1.967

Review 2.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

Review 3.  From Rust to Quantum Biology: The Role of Iron in Retina Physiopathology.

Authors:  Emilie Picard; Alejandra Daruich; Jenny Youale; Yves Courtois; Francine Behar-Cohen
Journal:  Cells       Date:  2020-03-13       Impact factor: 6.600

4.  Ocular findings in patients with transfusion-dependent β-thalassemia in southern Iran.

Authors:  Sezaneh Haghpanah; Omid Reza Zekavat; Mohammadreza Bordbar; Mehran Karimi; Soheila Zareifar; Sanaz Safaei; Mani Ramzi; Hossein Ashraf
Journal:  BMC Ophthalmol       Date:  2020-09-22       Impact factor: 2.209

5.  Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major.

Authors:  Raffaele Nuzzi; Giada Geronazzo; Federico Tridico; Alessia Nuzzi; Paolo Caselgrandi; Antonio Giulio Piga
Journal:  Clin Ophthalmol       Date:  2021-05-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.